Stocks on the Move: ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), FuelCell Energy, Inc. (NASDAQ:FCEL)
Northern, WI 05/27/2013 (GDPInsider) – ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is continuing its strong run in market valuation, having started the day’s trading at 2.10, 0.08 cents higher than previous close of 2.02. ZIOP is up 29.75% on extremely strong volume of 16.771 million. The range so far in this morning’s session is 2.0832 and 2.96, and the average volume is 2.292 million.
ZIOP hasn’t released any new developments since it announced plans to present at the 38th Annual Deutsche Bank Health Care Conference so it seems market valuation is baking in these developments and others that have flowed in the last few weeks.
ZIOP is up 52.61% on its 20-day simple moving average and 15.04% on its 50-day simple moving average with a target price of 2.88 set by analysts. The stock is down 58.59% on its 52-week high of 6.33 but up 75.91% on its 52-week low of 1.49. 83.56 million shares are outstanding in ZIOP and Institutions own 51.63% of the stock.
Is ZIOP a solid investment at these levels? Get exclusive data and trends here.
FuelCell Energy, Inc. (NASDAQ:FCEL) is up 28.81% in today’s trading after opening at 1.19, 0.01 cent above its previous close of 1.18. FCEL is trading on volume of 16.392 million, a whopping 1063.58% above average volume of 1.408 million. The stock has a range of 1.16 and 1.53 and is trading 9.35% above its 52-week high of 1.39 and 83.13% above its 52-week low of 0.83.
FCEL announced its imminent release of Q2 2013 financial results due on June 5, 2013. During this call participants will have live access via a webcast on the company website and over the telephone.
FCEL has had a relatively strong performance in the last few months and the company is expecting EPS to rise this year by 49.72% and a further 64.70% in 2014. The stock has a RSI of 84.65 indicating that current market valuation has taken it deep into overbought territory. The stock is however trading 40.87% above its SMA20 and 52.12% above its SMA50
How Should Investors Trade FCEL Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.